ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IDXG vs SXTC // EV/EBITDA & P/E VALUATION

Interpace Biosciences Inc. (NASDAQ) VS. China SXT Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: IDXG 6 — SXTC 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IDXG VS. SXTC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IDXG SXTC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 62.30% 21.90% +40.40 IDXG /gross-margins <GO>
Return on Invested Capital (ROIC) 16.20% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 4.7x — — TIE /valuation <GO>
Free Cash Flow Yield 23.60% — — TIE /fcf-yield <GO>
Operating Margin 10.50% -60.00% +70.50 IDXG /operating-margins <GO>
Net Profit Margin 63.50% -60.00% +123.50 IDXG /net-margins <GO>
Revenue Growth (YoY) -17.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 1/9 +5.00 IDXG /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.5 27.7 +23.76 IDXG /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $23.2M $367.7K $22.8M IDXG /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IDXG REV SXTC REV IDXG GROSS % SXTC GROSS % IDXG FCF SXTC FCF
FY 2025 $38.7M $1.1M 62.3% 21.9% $5.5M -$4.0M
FY 2024 $46.9M $1.7M 63.8% 21.1% $3.8M -$2.3M
FY 2023 $40.0M $1.9M — — $3.8M -$1.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IDXG // BETA —
SXTC // BETA —